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Abstract
Introduction: To assess in a prospective study the course and the predictors of microalbuminuria in children and adolescents with type 
1 diabetes.
Material and methods: 438 children and adolescents who developed diabetes in the years 1985–2004 were followed for 9.2 ± 3.4 years 
from the diagnosis. Microalbuminuria was assessed on the basis of timed overnight urine collections performed once per year. Variabil-
ity of glycated haemoglobin was expressed as a coefficient of variation (%) calculated by dividing standard deviation (adjusted for the 
number of measurements) by mean of HbA1c.
Results: Microalbuminuria was noted in 99 patients (22.6%) after 8.27 ± 3.3 years of diabetes. In 29 individuals (6.6%), microalbumi-
nuria was persistent. The prevalence of microalbuminuria was not dependent on the period of diabetes diagnosis. During follow-
up, 17 (58.6%) patients with persistent MA reverted to normoalbuminuria. Children without any episodes of microalbuminuria 
had significantly lower HbA1c variability (8.44%; 95% CI 7.81–9.08%) than those with one (10.28% 95% CI 9.10–11.47%; p = 0.007). 
The difference of HbA1c variability between patients with and without microalbuminuria persisted after correction by mean HbA1c 
(p = 0.04). Risk factors for ever developing microalbuminuria during the observation period in multivariate analysis included: 
mean HbA1c (HR [95% CI]: 1.17 [1.00–1.37; p = 0.05]) and its variability (1.04 [1.00–1.07]; p = 0.05), insulin dose (HR per 0.1 unit*kg
-
1*day–1: 0.87 [0.79–0.96]; p = 0.005), presence of arterial hypertension (1.63 [1.07–2.49]; p = 0.02), and age at onset of diabetes (1.15 
[1.08–1.21]; p < 0.0001). 
Conclusions: Children who develop microalbuminuria are characterised by poorer and more variable metabolic control, hinting at the 
importance of interventions aimed at both improvement and stabilisation of HbA1c levels. (Endokrynol Pol 2014; 65 (2): 83–89)
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Streszczenie
Wstęp: Mikroalbuminuria jest wskaźnikiem wczesnej fazy nefropatii cukrzycowej i czynnikiem ryzyka jej progresji, równocześnie 
obserwuje się znaczny odsetek samoistnej normalizacji albuminurii. Celem wieloletniego prospektywnego badania była ocena historii 
naturalnej i czynników ryzyka rozwoju mikroalbuminurii u dzieci i młodzieży z cukrzycą typu 1.
Materiał i metody: Przez 9,2 ± 3,4 lat od rozpoznania choroby obserwowano 438 dzieci, które zachorowały na cukrzycę w latach 1985–2005. 
Mikroalbuminurię oceniano w nocnych zbiórkach moczu wykonywanych każdego roku. Zmienność hemoglobiny glikowanej (HbA1c) 
wyrażono współczynnikiem zmienności (%) obliczonym jako iloraz odchylenia standardowego (adjustowanego do liczby pomiarów) 
i średniej HbA1c.
Wyniki: Mikroalbuminurię stwierdzono u 99 (22,6%) chorych po 8,27 ± 3,3 latach cukrzycy. U 29 (6,6%) dzieci mikroalbuminuria była 
obecna przez co najmniej 2 kolejne lata. Częstość mikroalbumiurii nie zależała od okresu rozpoznania cukrzycy. W czasie dalszej obser-
wacji u 17 (58,6%) badanych albuminuria uległa normalizacji. U dzieci bez epizodu mikroalbuminurii wykazano znamiennie mniejszą 
zmienność HbA1c (8,44%; 95% CI 7,81–9,08%) w porównaniu z chorymi z mikroalbuminurią (10,28% 95% CI 9,10–11,47%; p = 0,007).
Różnica ta była nadal obecna po uwzględnieniu średniej HbA1c (p = 0,04). Czynnikami ryzyka rozwoju mikroalbuminurii u dzieci 
w okresie wieloletniej obserwacji ujawnionymi w analizie wieloczynnikowej były: średnia HbA1c (HR [95% CI]: 1,17 [(1,00–1,37; p = 0,05]), 
zmienność HbA1c (1,04 [1,00–1,07]; p = 0,05), dawka insuliny (HR dla 0,1 j.*kg
–1*day–1: 0,87 [0,79–0,96); p = 0,005), nadciśnienie tętnicze 
(1,63 [1,07–2,49]; p = 0,02) i wiek zachorowania na cukrzycę (1,15 [1,08–1,21]; p < 0,0001). 
Wnioski: Dzieci, u których rozwinęła się mikroalbuminuria charakteryzowały się gorszą i bardziej zmienną kontrolą metaboliczną cukrzycy 
stąd w leczeniu należy zwrócić uwagę zarównano na poprawę jak i stabilizację HbA1c. (Endokrynol Pol 2014; 65 (2): 83–89)
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Introduction
Microalbuminuria was initially regarded as the early 
marker of incipient diabetic nephropathy — stage III 
of diabetic kidney disease according to the Mogensen 
classification, which progressed to overt proteinuria 
and to end stage renal disease in up to 80% of patients 
in older studies and in 14% in more recent publications 
[1, 2]. Later, after the analysis of renal biopsy specimens, 
it was proved that diabetic patients with microalbumi-
nuria may have advanced glomerulopathy and dem-
onstrate renal function impairment. In these subjects, 
microalbuminuria is rather the indicator of existing 
structural kidney abnormalities and not only the risk 
marker [3]. This implicated the recommendations of 
different diabetes societies (including ISPAD guidelines) 
to introduce some treatment modalities i.e. ACE inhibi-
tors or AT2 blockers to reduce microalbuminuria and 
delay or stop the progression of kidney disease [4–6]. 
On the other hand, some studies have reported the 
regression of microalbuminuria in more than 50% of 
adults and up to 50% of adolescents even without any 
intervention [2, 7–13]. Such natural course of the disease 
brings into question the necessity of pharmacological 
treatment implementation, especially in diabetic chil-
dren and adolescents. There is no consensus on the fre-
quency of diabetic nephropathy and microalbuminuria, 
as some reports evidence decreasing prevalence, while 
others show no improvement despite the intensifica-
tion of diabetes control and pharmacological therapy 
[14–17]. Another important conclusion suggested on 
the basis of recent studies is that microalbuminuria is 
reversible even without any intervention. Thus, the 
predictive value of microalbuminuria as the marker 
of incipient diabetic nephropathy in children has also 
been challenged.
The aim of this prospective study was to assess 
the prevalence and the course of microalbuminuria in 
diabetic children and adolescents after a long follow-up 
period and establish the predictors of microalbuminuria 
development in a paediatric population. Secondly, we 
planned to evaluate the impact of variability of meta-
bolic control on the risk of developing microalbuminu-
ria in children with diabetes. 
Material and methods
The study population included children and ado-
lescents, inhabitants of the Malopolska region in 
Poland, who developed type 1 diabetes mellitus in 
the years 1985 to 2004. All patients with newly diag-
nosed type 1 diabetes (according to WHO criteria) 
were referred to the University Children’s Hospital 
in Cracow and remained under the care of the Endo-
crinology Department of the hospital thereafter. In 
our routine practice, each patient visited the diabetes 
clinic at least four times a year. At each visit, a physi-
cal examination was performed and weight, height, 
BMI, blood pressure, glycated haemoglobin (HbA1c) 
and insulin dose were recorded. Additionally, start-
ing two years after the diabetes onset, all patients 
underwent lipid profile examination, urine analysis 
(to exclude infection), screening for retinopathy and 
microalbuminuria once per year. The mean time of 
follow-up was 9.2 ± 3.4 years. The protocol of pa-
tients’ evaluation was approved by the Jagiellonian 
University ethics committee and informed consent 
was obtained from patients and their parents.
Albumin excretion rate (AER) was estimated in 
timed, overnight urine collections (collection time 
7–9 hours). In cases of AER value above the reference 
range for healthy children and adolescents (> 10 μg/min), 
two additional urine collections were performed 
within 3–6 months. Microalbuminuria was defined 
as AER ≥ 20 μg/min and < 200 μg/min in at least two 
samples obtained within the period of 3-6 months. Mi-
croalbuminuria observed in two or more consecutive 
years, i.e. two or more samples with AER ≥ 20 μg/min in 
at least two years in a row, was regarded as persistent.
We identified 438 individuals with complete data re-
cords i.e.: anthropometric measurements, albuminuria 
and retinopathy screening, blood pressure, HbA1c, total 
cholesterol, LDL, HDL and TG assessment who were 
followed annually for at least five years. The analysed 
endpoint was the first episode of microalbuminuria.
Urinary albumin was measured with double anti-
body radioimmunoassay (Immunotech, Prague, Czech 
Republic). The intra-assay coefficient of variation was 
≤ 6.1%, and the inter-assay coefficient of variation was 
≤ 10%.
HbA1c was assessed with high performance liquid 
chromatography (Variant II Haemoglobin Testing 
System, BioRad Laboratories) until 2007, and immu-
noturbidimetry (Vitros 5.1 FS Chemistry System, Ortho 
Clinical Diagnostics, Johnson and Johnson) thereafter. 
Comparison of both methods revealed a correlation 
coefficient r = 0.96. To convert values obtained by differ-
ent methods, the following equation was used: Variant 
= 1.5685 + 0.74776 Vitros. Reference range for HPLC 
method was: 4.5–6.1%. The assay was DCCT-aligned.
Lipids: serum total cholesterol, LDL, HDL choles-
terol and triglycerides were measured enzymatically 
in samples collected in fasting conditions using an 
autoanalyser (Vitros 5,1 FS Chemistry System, Ortho 
Clinical Diagnostics, Johnson and Johnson), LDL cho-
lesterol was determined directly.
Blood pressure was measured with a standard 
mercury sphygmomanometer in patients seated, after 
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10–15 minutes of rest. Patients with blood pressure 
> 95th percentile for sex, height and age were diag-
nosed with arterial hypertension (HA). Percentile tables 
from the Fourth Report on the Diagnosis, Evaluation, 
and Treatment of High Blood Pressure in Children and 
Adolescents were used [18]. 
BMI z-score was calculated using Polish national 
data [19]. 
Statistical analysis
Continuous variables entering the analysis were 
mean values of each analysed parameter computed 
using baseline values and all subsequent measure-
ments until reaching the endpoint or the end of 
observation (transfer of the patient to an adult dia-
betology clinic). Variability of HbA1c was expressed as 
coefficients of variation (CV) computed as (Average/ 
/Standard Deviation)*100%. In order to circumvent 
the dependence of SD upon the number of measure-
ments, we used the  correction [20]. The presence of 
HA at baseline assessment was used in the analysis 
due to subsequent different therapeutic approaches 
and an inability to determine actual compliance 
to pharmacological treatment. As the first line of 
hypertension management, nonpharmacological 
intervention was recommended, and in cases of 
no improvement ACE inhibitors were introduced. 
Statistical analysis was performed using a two stage 
approach. Initial univariate analysis was used to 
screen for variables likely to be associated with the 
endpoint (microalbuminuria) occurring for the first 
time during the observation period. To do so, we used 
univariate Cox regression analysis to select variables 
with a p value < 0.15. Those that met this criterion 
entered a multivariate backward stepwise model 
building procedure in search of one with a p value 
lower than 0.05 considered as statistically significant. 
Statistica 10.0 package (Statsoft, Tulsa, OK, USA) was 
used for statistical analysis.
Results
General characteristics of the study group are presented 
in Table I. 
Out of 438 patients, 99 (22.6%) developed mi-
croalbuminuria after 8.27 ± 3.3 years of diabetes. 
Persistent microalbuminuria was found in 29 (6.6%) 
participants, 19 boys and ten girls. In 60 (13.7%) pa-
tients, microalbuminuria was transient and reverted 
to normal range after one year and in ten (2.3%) 
subjects microalbuminuria was intermittent (Fig. 1). 
During the follow-up period of 9.2 ± 3.4 years (range 
5–18.6 years), 17 (58.6%) patients with persistent mi-
croalbuminuria reverted to normoalbuminuria after 
2–3 years and remained normoalbuminuric until the 
end of the observation (median 3 years, range 1–7). 
Of those individuals, only two patients received 
ACE-inhibitor because of concomitant hyperten-
sion. We found no difference in the mean HbA1c 
before the development of microalbuminuria and 
during the follow-up period in patients with the nor-
malisation of AER (8.25 ± 1.4 v. 8.28 ± 1.1%). In two 
subjects, microalbuminuria persisted for 4–5 years 
before discharge from the clinic, and in the remain-
ing ten patients with persistent microalbuminuria 
there was no follow-up data available because they 
were transferred to an adult clinic after two years 
of microalbuminuria presence. None of the patients 
developed macroalbuminuria during the period of 
analysis. Background retinopathy was found in two 
patients with persistent microalbuminuria (including 
one who regressed to normoalbuminuria after two 
years). All but one patient with persistent microal-
buminuria had low-grade values of AER (mean 39.1 
± 17.9 μg/min.). We did not observe a change in the 
prevalence of microalbuminuria dependent on the 
year of diagnosis of diabetes since 1985 (p = 0.53 for 
differences between patients with onset of diabetes 
in the years 1985–1990, 1991–1995 and 1996–2000). 
Risk factors for the development of microalbumi-
nuria
Univariate analysis allowed the authors to identify 
five variables potentially associated with the risk 
of developing microalbuminuria both in a time-
dependent and time-independent manner. These 
variables included: age at onset of diabetes, presence 
of arterial hypertension at baseline, mean HbA1c 
concentration throughout the observation period, 
variability of HbA1c (CV), and mean insulin dose (Ta-
ble I). Multivariate Cox regression analysis yielded 
a final model showing that factors independently as-
sociated with the risk of developing the first episode 
of microalbuminuria were: the presence of arterial 
Figure 1. The course of microalbuminuria in type 1 diabetic 
children
Rycina 1. Historia naturalna mikroalbuminurii u dzieci chorych 













HbA1c variability and microalbuminuria in T1DM  Joanna Nazim et al.
hypertension, age at onset of diabetes, HbA1c level 
and its CV and insulin dose per kg (Table II). Kaplan-
Meier curves computed for three HbA1c thresholds 
are presented in Figure 2A and the effect of HbA1c 
variability is shown in Figure 2B. Sex-standardised 
BMI did not maintain statistical significance in the 
multivariate model. Children without any episodes 
of microalbuminuria had significantly lower HbA1c 
variability (8.44%; 95% CI 7.81–9.08%) than those with 
one (10.28% 95% CI 9.10–11.47%; p = 0.007). The dif-
ference in HbA1c variability between patients with and 
without microalbuminuria persisted after correction 
by mean HbA1c (p = 0.04), regardless of the number 
of microalbuminuria episodes. No significant differ-
ences were noted between patients with one or more 
episodes of microalbuminuria (p = 0.95). 
Table I. General characteristics of the study group
Tabela I. Ogólna charakterystyka grupy badanej
Variables The whole study group Children with MA Children without MA HR (95%CI)
Sex (M/F) 241/197 58/41 183/156 0.87 (0.58–1.29)
Age at onset (years) 8.77 ± 3.6 9.11 ± 3.63 8.68 ± 3.59 1.17 (1.10–1.23)*
Arterial hypertension at baseline (absent/
present)
367/71 72/27 295/44 0.69 (0.46–1.03)*
BMI1 Z-score –0.05 ± 0.67 –0.17 ± 0.63 –0.02 ± 0.68 0.76 (0.56–1.03)
Mean HbA1c (%) 7.89 ± 1.39 8.39 ± 1.71 7.95 ± 1.28 1.16 (1.00–1.34)*
CV of HbA1c (%) 8.86 ± 5.99 10.29 ± 5.93 8.44 ± 5.95 1.03 (1.00–1.07)*
Mean insulin dose  
(in 0.1 U/kg)
8.83 ± 2.21 8.47 ± 2.11 8.94 ± 2.23 0.85 (0.77–0.93)*
Mean Chol [mmol/L] 4.43 ± 0.76 4.43 ± 0.81 4.47 ± 0.74 0.92 (0.69–1.23)
Mean TG [mmol/L] 0.82 ± 0.31 0.81 ± 0.35 0.83 ± 0.30 0.79 (0.40–1.58)
Mean LDL [mmol/L] 2.46 ± 0.69 2.41 ± 0.73 2.48 ± 0.69 0.97 (0.70–1.35)
Mean HDL [mmol/L] 1.61 ± 1.96 1.49 ± 0.36 1.51 ± 0.35 1.00 (0.52–1.93)
Data is presented as means with standard deviations unless noted otherwise. MA — microalbuminuria; HR — hazard ratio; HbA1c — glycated haemoglobin; 95%CI — 
95% confidence Interval. Variables marked with an *differed significantly with a p value < 0.15 and entered multivariate analysis
Table II. Multivariate analysis results of factors affecting the 
risk of developing the first microalbuminuria episode
Tabela II. Wyniki analizy wieloczynnikowej czynników 
ryzyka rozwoju epizodu mikroalbuminurii
Parameter 
Estimate
P value HR HR (95% CI)
Age at onset 0.14 < 0.0001 1.15 1.08–1.21
Mean HbA1c 0.16 0.04 1.18 1.00–1.38
Mean daily insulin 
dose
–0.14 0.005 0.87 0.79–0.96 
CV of HbA1c 0.04 0.049 1.04 1.00–1.08
HA 0.25 0.02 1.63 1.07–2.49
HR — hazard ratio; 95%CI — 95% Confidence Interval; HbA1c — glycated 
haemoglobin
Figure 2. Estimated Kaplan-Meier curves for specific values of risk 
factors associated with microalbuminuria: glycated hemoglobin 
(A) and HbA1c variability (B) 
Rycina 2. Krzywe Kaplana-Meiera dla wybranych wartości 
czynników ryzyka mikroalbuminurii: Hemoglobina glikowana 
(A) i zmienność HbA1c (B)
87













We analysed the results of a long term prospective 
study of AER in a cohort of type 1 diabetic children 
and adolescents treated in a tertiary paediatric diabetes 
centre in Poland. The prevalence of microalbuminuria 
and persistent microalbuminuria in our patients was 
comparable to that reported in the current literature. 
The cumulative prevalence of any microalbuminuria 
in children was 9% to 25.7% and persistent microal-
buminuria from 4.5% to 18% after up to ten years of 
diabetes [11–13, 21–23]. 
The data concerning the change in the frequency 
of microvascular complications in diabetic children 
during the previous 20 years is not consistent. Downie 
et al. [24], after analysing complications in adolescents 
stratified by four time periods, reported an initial 
declining rate of microalbuminuria from 1990 to 2000 
which remained unchanged from 2000. This observa-
tion however was not confirmed by others [25]. Ac-
cording to Amin et al. [25], no change was shown in 
the frequency of any microalbuminuria in long term 
follow-up. These differences cannot be explained only 
by the change in the quality of diabetes control. In both 
the reports of Downie et al. and Amin and al., HbA1c 
of their patients had unsatisfactory metabolic control 
(HbA1c levels above 8%). But in the cohort described by 
Amin et al. no significant improvement was achieved 
during the follow-up, while Downie documented an 
initial significant decline of HbA1c after the intensifica-
tion of insulin therapy regimen. In our data, no change 
was found in the prevalence of any microalbuminuria 
and persistent microalbuminuria dependent on the 
year of diabetes diagnosis. Analysis of metabolic con-
trol in our centre expressed by HbA1c values showed 
significant improvement during the last 15 years. 
Yearly mean HbA1c decreased from 10.4% in 1990 to 
7.4% in 2005 [26], which may partially explain the 
low frequency of persistent microalbuminuria in our 
patients which was mainly low-grade and the high 
rate of microalbuminuria regression compared to our 
previous observations [27].
Many factors, some of them potentially modifiable, 
may influence the development of microalbuminuria 
in children. The most important one is glycaemic 
control. Suboptimal values of HbA1c are indicated in 
many papers as a risk factor of persistent microalbumi-
nuria and diabetic nephropathy [11–13, 22, 28–30] and 
patients with microalbuminuria have usually worse 
diabetes control than subjects without this condition. 
Our data confirms the importance of diabetes control 
in the process of the development of microalbumi-
nuria. Striving to achieve the best possible control 
of glycaemia from the onset of diabetes in children 
irrespective of age is fully justified. The availability 
of better tools for therapy and monitoring of diabetes 
enables attainment of this goal without the increased 
risk of hypoglycaemia [24]. Other predictive factors 
with conflicting data on their significance include: age 
at onset of diabetes [11, 12, 21, 22], duration of diabetes 
[12, 13, 22, 23], gender [13, 21], arterial hypertension 
[21, 22], dyslipidemia [22] and puberty [11, 13, 29, 31, 
32]. In our patients, factors that significantly influenced 
the risk of microalbuminuria development, besides 
HbA1c, were modifiable variables like the presence 
of hypertension at baseline and daily insulin dose. 
Higher insulin requirement is frequently linked to 
insulin resistance and accompanied by a higher BMI. 
The explanation of the beneficial effect of higher 
insulin supply in our patients may represent better 
adjustment of insulin doses to individual needs, all 
the more as our patients were not overweight. 
The important finding is the high rate of the 
regression of persistent microalbuminuria in our co-
hort (at least 60%). We were not able to estimate the 
real reversibility rate of microalbuminuria because 
in the remaining 40% of our microalbuminuric pa-
tients, persistent microalbuminuria developed just 
before the transfer to the adult clinic and they were 
lost to longer follow-up. It should be underlined 
however, that the normalisation of AER did not 
depend on pharmacological intervention (data not 
shown). Only two patients were treated with ACE 
inhibitors because of concomitant increase of blood 
pressure. There is limited evidence that the use of 
ACE inhibitors in adolescents and children decreases 
the albumin excretion rate and reverses structural 
changes within the kidney [33]. The normalisation 
of increased AER in microalbuminuric patients may 
not correspond to the improvement of renal struc-
tural lesions [34]. On the other hand, decreased GFR 
rarely occurs in diabetic patients without preceding 
microalbuminuria [35]. 
There are several reports of a high rate of micro-
albuminuria regression in type 1 diabetic patients 
but a direct comparison of the results is not possible 
because of different durations of follow-up, defini-
tions of microalbuminuria, and the inclusion into the 
analysis of patients with transient elevation of AER 
[7, 11, 12, 21]. Microalbuminuria in our patients was 
characterised by rather low intensity (below 100 μg/
min) and short duration, which may explain the high 
rate of the normalisation. In some of them, elevation 
of AER might be triggered by puberty and regression 
of microalbuminuria was the consequence of the end 
of the pubertal period. Age at onset of diabetes was 
an independent risk factor for the development of 
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additionally underlines the importance of endocrine 
changes during the puberty period for the manifesta-
tion of microalbuminuria, even in diabetics with very 
short disease duration [36]. Factors which showed 
significant association with the odds of developing 
microalbuminuria additionally included BMI and 
variability of HbA1c. BMI did not retain significance 
after multivariate analysis, although earlier reports 
have shown that patients with higher BMI Z-scores 
were protected from developing microalbuminuria 
with the underlying mechanism still unknown [37]. 
With regard to variability of HbA1c, the effect was 
surprisingly pronounced, particularly considering 
the adjustment for mean HbA1c level. In view of the 
available data, we hypothesise that variability of HbA1c 
may represent a ‘breakthrough’ effect of a sudden 
deterioration of metabolic control with the associated 
episode of microalbuminuria, both of which are sub-
sequently resolved. If this is the case, protection from 
such events may be offered by interventions aimed at 
reducing the variability of HbA1c, such as the introduc-
tion of insulin pump therapy [38]. The significance of 
HbA1c variability as a risk factor of microalbuminuria 
development in patients with type 1 and type 2 dia-
betes has been confirmed recently [39, 40].
The limitation of this study is a lack of longer 
follow-up in some patients after the development of 
persistent microalbuminuria. This may have resulted 
in an underestimated effect of metabolic control and its 
variability, as fewer measurements could lead to a lower 
CV in children with persistently high HbA1c and trun-
cated observations. We also did not use Tanner stage to 
indicate the onset of puberty, but the significance of age 
at onset of diabetes explained the influence of puberty 
on the risk of microalbuminuria. 
In conclusion, the results of this long-term clinic-
based study indicate that microalbuminuria in type 
1 diabetic children and adolescents is frequently low 
grade and reversible in the majority of patients even 
without pharmacological intervention. Major risk fac-
tors for developing microalbuminuria in diabetic chil-
dren are modifiable by therapeutic actions not necessar-
ily focused on nephrologic treatment, underlining the 
significance of metabolic control and adequate insulin 
dosage. Children who develop microalbuminuria are 
characterised by poorer and more variable metabolic 
control, hinting at the importance of interventions 
aimed at both improvement and stabilisation of HbA1c 
levels.
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